Carisma Therapeutics

CARMPhase 1

Carisma Therapeutics is focused on developing a new class of immunotherapies by engineering macrophages, which are innate immune cells capable of infiltrating solid tumors and modulating the tumor microenvironment. The company's lead candidate, CT-0508, is in Phase 1 clinical trials for HER2-overexpressing solid tumors, representing a first-in-class approach. Carisma has established strategic collaborations with industry leaders like Moderna and Sesen Bio to expand its platform and pipeline. Despite being a clinical-stage company with no approved products, it has attracted significant investment and attention for its innovative technology.

Market Cap

$1.5M

Employees

50-100

Focus

Biotech

CARM · Stock Price

USD 0.0413.88 (-99.74%)

Historical price data

AI Company Overview

Technology Platform

Proprietary Chimeric Antigen Receptor Macrophage (CAR-M) platform that engineers a patient's own macrophages to target and destroy solid tumor cells, with potential for allogeneic and in vivo applications.

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage	Watch
CT-0508 + Pembrolizumab	HER2-positive	Phase 1
CT-0525	HER2-positive	Phase 1

Funding History

Total raised: $180.5M

IPO$80.5MUndisclosedJan 26, 2023

Series B$47MTPG BiotechMay 15, 2020

Series A$53MAbbVie VenturesJan 15, 2018

Opportunities

Carisma's primary opportunity is to successfully demonstrate clinical proof-of-concept for its CAR-M platform, which could unlock a massive market in solid tumor oncology.

The collaborations with Moderna for in vivo CAR-M and the potential of its allogeneic program represent significant long-term value drivers that could expand the platform's applicability and scalability.

Risk Factors

Key risks include clinical failure of its lead asset CT-0508, the immense technical and financial challenges of scaling autologous cell therapy manufacturing, a limited cash runway requiring future dilutive financing, and intense competition from both established therapies and novel modalities in solid tumor treatment.

Competitive Landscape

Carisma competes in the emerging field of engineered innate immune cell therapy against other CAR-M developers like Myeloid Therapeutics. Its broader competitive set includes advanced CAR-T companies targeting solid tumors, established antibody-drug conjugates, and other immunotherapy modalities. Its differentiation lies in the unique biology of macrophages for solid tumor infiltration and microenvironment modulation.